| Literature DB >> 21842293 |
I Hinterseher1, G Gäbel, F Corvinus, C Lück, H D Saeger, H Bergert, G Tromp, H Kuivaniemi.
Abstract
Infectious agents are likely to play a role in the pathogenesis of chronic inflammatory diseases, including abdominal aortic aneurysms (AAAs). The goal of this study was to determine if Borrelia burgdorferi sensu lato (sl), a microorganism responsible for Lyme disease, is involved in the etiology of AAAs. The presence of serum antibodies against B. burgdorferi sl was measured with enzyme-linked immunosorbent assay (ELISA) and confirmed by Western blotting in 96 AAA and 108 peripheral artery disease (PAD) patients. Polymerase chain reaction (PCR) was used for the detection of Borrelia-specific DNA in the aneurysm wall. Among AAA patients 34% and among PAD patients 16% were seropositive for B. burgdorferi sl antibodies (Fisher's exact test, p = 0.003; odds ratio [OR] 2.79; 95% confidence interval [CI] 1.37-5.85). In the German general population, 3-17% are seropositive for Borrelia antibodies. No Borrelia DNA was detected in the aneurysm wall. Our findings suggest a relationship between AAAs and B. burgdorferi sl. We hypothesize that the underlying mechanism for B. burgdorferi sl in AAA formation is similar to that by the spirochete Treponema pallidum; alternatively, AAAs could develop due to induced autoimmunity via molecular mimicry due to similarities between some of the B. burgdorferi sl proteins and aortic proteins.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21842293 PMCID: PMC3319877 DOI: 10.1007/s10096-011-1375-y
Source DB: PubMed Journal: Eur J Clin Microbiol Infect Dis ISSN: 0934-9723 Impact factor: 3.267
Characteristics of the study groups
| AAA ( | PAD ( |
| |||
|---|---|---|---|---|---|
| Age, mean ± SD (years) | 72.3 | ± 9.1 | 69.1 | ± 9.6 | 0.013 |
| Men (%) | 89/96 | (93) | 94/108 | (87) | 0.249 |
| PAD (%) | 15/78 | (41) | 108/108 | (100) | <2.2 × 10−16 |
| Coronary artery disease (%) | 30/78 | (39) | 44/107 | (41) | 0.762 |
| Hypertensiona (%) | 67/77 | (87) | 97/107 | (91) | 0.477 |
| Diabetes mellitus (%) | 21/77 | (27) | 46/107 | (43) | 0.031 |
| Dyslipidemiab (%) | 50/77 | (65) | 87/107 | (81) | 0.016 |
| Aspirin (%) | 61/74 | (82) | 80/106 | (76) | 0.278 |
| Clopidogrel (%) | 3/74 | (4.1) | 36/106 | (34) | 6.9 × 10−7 |
| Calcium antagonists (%) | 24/74 | (32) | 36/106 | (34) | 0.873 |
| ACE inhibitors (%) | 45/74 | (61) | 56/106 | (53) | 0.360 |
| Diuretics (%) | 38/74 | (51) | 54/106 | (51) | 1.000 |
| Beta-blockers (%) | 56/74 | (76) | 60/106 | (57) | 0.011 |
| Statins (%) | 48/74 | (65) | 84/106 | (79) | 0.040 |
| Corticosteroids (%) | 3/74 | (4.1) | 1/106 | (0.9) | 0.307 |
| Hemoglobin (mmol/l) | 8.2 | ± 1.2 | 8.1 | ± 1.2 | 0.379 |
| Hematocrit | 0.39 | ± 0.1 | 0.39 | ± 0.1 | 0.590 |
| White blood cell count ( × 109/l) | 8.6 | ± 3.9 | 8.1 | ± 2.4 | 0.935 |
| Thrombocyte count ( × 109/l) | 211.9 | ± 67.2 | 257.6 | ± 98.1 | 0.00005 |
| HbA1c (%) | 6.6 | ± 1.3 | 6.3 | ± 0.8 | 0.553 |
| C-reactive protein (mg/l) | 21.5 | ± 41.2 | 17.4 | ± 32.8 | 0.300 |
| Cholesterol (mmol/l) | 4.7 | ± 1.3 | 4.7 | ± 1.4 | 0.363 |
| LDL (mmol/l) | 2.9 | ± 1.0 | 2.6 | ± 1.1 | 0.037 |
| HDL (mmol/l) | 1.2 | ± 0.4 | 1.2 | ± 0.4 | 0.998 |
| Triglycerides (mmol/l) | 1.9 | ± 2.0 | 13.7 | ± 56.7 | 0.143 |
| Creatinine (mmol/l) | 113.5 | ± 41.9 | 103.6 | ± 99.3 | 2.9 × 10−5 |
Comparisons between cases and controls were carried out using multivariate logistic regression. The number of individuals in each study group for whom the information was available is indicated. Laboratory parameters are shown as mean ± standard deviation (SD) and were measured preoperatively
aBlood pressure ≥ 140/90 mmHg
bIncreased LDL (male and female: ≥ 4.12 mmol/l; age > 35 years) and decreased HDL (male: ≤ 0.90 mmol/l;female ≤ 1.3 mmol/l; age > 35 years)
Fig. 1Seroprevalences in different risk groups in Germany [59–64]. Only studies with both enzyme-linked immunosorbent assay (ELISA) and immunoblotting data were included. The confidence intervals for binomial probabilities were calculated in R [23]
Summary of immunoblotting results for abdominal aortic aneurysm (AAA) and peripheral artery disease (PAD) patients
|
| Immunoblota result | Number (%)b of positive samples in: | |
|---|---|---|---|
| AAA, | PAD, | ||
|
| VlsE | 30 (91) | 17 (100) |
| OspC | 5 (15) | 1 (6) | |
| BmpA | 5 (15) | 2 (12) | |
| p83c | 6 (18) | 5 (29) | |
| BBO323c | 2 (6) | – | |
| BBA36c | 1 (3) | – | |
| Crasp3c | 3 (9) | – | |
|
| DbpA-PKo | 20 (61) | 13 (76) |
|
| p58 | 8 (24) | 8 (47) |
aDescription of the bands seen in immunoblots: VlsE “vmp (variable major protein)-like-sequence E”, in vivo experiment B. burgdorferi lipoprotein with conserved highly immunogenic epitopes, which is a species-independent main marker in Borrelia diagnostics; OspC “outer surface protein C”, a highly variable surface protein of the B. burgdorferi sl group, early IgM marker of the B-cell immune response; BmpA “borrelial membrane protein A”, main marker of IgG serology for disseminated Lyme borreliosis; p83 highly conserved antigen in the B. burgdorferi sl group, an IgG marker of late-stage borreliosis; BB0323 a hypothetical protein identified in strain B31 of B. burgdorferi sl by genome analysis and verified by epitopes in vivo, marker of late-stage borreliosis, frequently positive in neuroborreliosis; BBA36 a lipoprotein of unknown function of B. burgdorferi sl strain B31, verified by epitopes in vivo, marker of late-stage borreliosis; Crasp3 “complement regulator-acquiring surface protein 3”, marker of late-stage borreliosis; DbpA-PKo “decorin-binding protein A”, highly specific marker for B. afzelii; p58 “oligopeptide permease protein A-2”, marker for B. garinii
bThe percentages indicate the proportion of samples positive for the given marker among all positive samples
cMarkers for late-stage borreliosis
Summary of studies investigating the presence of serum antibodies against microorganisms in AAA patients
| Microorganism | Study design | Sample number | IgG serum Ab (%)a, cases/controls | DNA in the AAA wall (%)b, cases/controls | Study |
|---|---|---|---|---|---|
|
| Case only | 51 | 80/– | 51/– | Blasi et al., 1996 [ |
| Case only | 12 | 67/– | 50/– | Juvonen et al., 1997 [ | |
| Case only | 139c | 75/– | ND | Lindholt et al., 1999 [ | |
| Case only | 22 | 54/– | ND | Halme et al., 1999 [ | |
| Case–control | 81/56 | 96/88 | ND | Blanchard et al., 2000 [ | |
| Case only | 102 | 61/– | 32/– | Porqueddu et al., 2002 [ | |
| Case–control | 119/36 | 74/72 | ND | Nyberg et al., 2007 [ | |
| Case–control | 68/68 | 47/37 | 0/0d | Falkensammer et al., 2007 [ | |
| Case only | 211c | 76/– | ND | Karlsson et al., 2009 [ | |
| Case–control | 50/110 | 82/77 | ND | Vikatmaa et al., 2010 [ | |
| Case–control | 42/100 | 82/70 | ND | Karlsson et al., 2011 [ | |
|
| Case only | 51 | 92/– | 0/– | Blasi et al., 1996 [ |
|
| Case–control | 96/108 | 34/16 | 0/–e | Present study |
aThe numbers indicate the percentage of positive samples in each study group
bThe presence of microorganism-specific DNA sequences in aortic wall tissue samples was assayed by PCR-based techniques
cStudy on AAA expansion
dNew sample set of 30 cases/15 controls. These samples were also tested for the presence of Borrelia DNA and all samples were negative for Borrelia DNA
eAnalyzed in ten seropositive and 16 seronegative cases
ND not determined